Offer Description The Childhood Cancer & Blood Disorders group at VHIR is composed of clinical, translational and basic researchers and has three laboratories (Sarcomas lab, Neural Tumors lab and Rare Anemia Disorders lab) and three research programs (Personalized Medicine, Clinical Trials Unit and Stem Cell & Advanced Therapies Hematological Malignancies & Cell Therapy).
Pediatric cancer has specific features that define it as an entity that in the majority of cases is certainly different from adult tumors; i.e.
etiology, biology, response to treatment and prognosis are significantly different.
The implementation of multimodal treatments (i.e.
combinations of chemotherapies, radiotherapies, biological agents…) in the last 20 years has enabled the increase in patient survival around 80%.
Although the global survival of pediatric cancer is around 80%, patients with some types of tumors present a much lower survival.
Moreover, almost two-thirds of patients who survive suffer severe side effects due to the treatment.
Therefore, the development of therapies to treat 20% of patients who do not survive and to reduce toxicity of current treatments avoiding long-term side effects is extremely necessary.
The main objective of Neural tumor laboratory is to implement the use of epigenetic therapies, that is, therapies against gene expression modulators that, in turn, regulate several genes, pathways or cellular processes, without affecting the DNA sequence.
The laboratory focuses on neuroblastoma, a pediatric solid tumor of the peripheral nervous system, and on pediatric brain tumors of the central nervous system such as ependymoma, medulloblastoma or high-grade glioma among others.
Main responsibilities and duties: - Full-time position: 40h/week.
- In vitro and In vivo drug screening and efficacy studies.
- Prepare presentation of results and communication/dissemination material.
- Participation in laboratory outreach activities.
Requirements: Research Field: Biological sciences Education Level: PhD or equivalent Education and qualifications: Required: - Bachelor's Degree in Sciences (Biology, Biochemistry, Pharmacy, Biotechnology, Genetics, Medicine, etc.)
and Master - PhD in Cancer Biology.
Desired: - Good command of Spanish & English (C1/C2 level).
Experience and knowledge: Required: - Experience in drug development projects.
Desired: - Good communication skills and good team player - International internship.
Additional Information: Benefits: Labour conditions: - Starting date: February 2025 - Gross annual salary: Remuneration will depend on experience and skills.
Salary ranges are consistent with our Collective Agreement pay scale.
- Contract: Technical and scientific activities contract linked to the project activities.
What can we offer?
- Incorporation to Vall d'Hebron Research Institute (VHIR), a public sector institution that promotes and develops biomedical research, innovation and teaching at Vall d'Hebron University Hospital (HUVH), the biggest hospital of Barcelona and the largest of Catalan Institute of Health (ICS).
- A scientific environment of excellence, highly dynamic, where high-end biomedical projects are continuously developed.
- Continuous learning and a wide range of responsibilities within a stimulating work environment.
- Individual training opportunities.
- Flexible working hours.
- 23 days of holidays + 9 personal days.
- Flexible Remuneration Program (including dining checks, health insurance, transportation and more) - Corporate Benefits: platform through which you can obtain significant discounts on travel, culture, technology, gastronomy, sports... among many others.
- Healthy Offering: choose from a variety of wellbeing focused activities to be the healthiest you.
Selection process: Deadline to apply: 26-12-2024 Additional comments: VHIR embraces Equality and Diversity.
As reflected in our values we work toward ensuring inclusion and equal opportunity in recruitment, hiring, training, and management for all staff within the organization, regardless of gender, civil status, family status, sexual orientation, gender identity and expression, religion, age, functional diversity or ethnicity.
#J-18808-Ljbffr